Zynerba's cannabis-based drug for rare genetic disorder fails study [Reuters]
Zynerba Pharmaceuticals, Inc. (ZYNE)
Last zynerba pharmaceuticals, inc. earnings: 3/10 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.zynerba.com
Company Research
Source: Reuters
Zynerba's cannabis-based drug for rare genetic disorder fails study (Reuters) - Zynerba Pharmaceuticals Inc said on Tuesday its experimental cannabis-based gel Zygel was not statistically significant in improving aberrant behavior when compared to a placebo in patients with a neurological disorder called Fragile X syndrome. The company’s shares plunged 48.5% to $3.37 before the opening bell. The drug, which also did not meet secondary goals of the 212-patient study, is a synthetic version of cannabidiol - a component of the cannabis plant. The company said a pre-planned analysis of patients most severely impacted by the disease did show statistically significant improvement in behavior at week 12. Based on the data, Zynerba plans to meet with the U.S. Food and Drug Administration for a path forward for Zygel. Fragile X syndrome (FXS) is characterized by mild-to-moderate intellectual disability.
Show less
Read more
Impact Snapshot
Event Time:
ZYNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZYNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZYNE alerts
High impacting Zynerba Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics